<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414165</url>
  </required_header>
  <id_info>
    <org_study_id>Tg 511-15-01</org_study_id>
    <secondary_id>FD-R-5732</secondary_id>
    <nct_id>NCT02414165</nct_id>
  </id_info>
  <brief_title>The Toca 5 Trial: Toca 511 &amp; Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma</brief_title>
  <acronym>Toca5</acronym>
  <official_title>A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tocagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tocagen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus
      standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine
      or temozolomide) or bevacizumab administered to subjects undergoing resection for first or
      second recurrence (including this recurrence) of GBM or AA. Subjects meeting all of the
      inclusion and none of the exclusion criteria will be randomized prior to surgery in a 1:1
      ratio to receive either Toca 511 and Toca FC (Experimental arm, Arm T) or control treatment
      with one option of standard of care (Arm SOC). Stratification will be done by IDH1 mutation
      status. A second stratification factor is based on the patient's Karnofsky Performance Score
      (KPS) (70-80 vs 90-100). Further, to account for potential differences in treatment choices
      for the control arm in regions, the trial will be stratified by geographical region during
      the randomization process.

      Funding Source - FDA OOPD
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytoma</measure>
    <time_frame>30 December 2019</time_frame>
    <description>Time from randomization date to death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durable Response Rate (CR or PR ≥ 24 weeks)</measure>
    <time_frame>30 December 2019</time_frame>
    <description>The proportion of patients whose best response is either CR or PR lasting at least 24 weeks, according to modified RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable Clinical Benefit Rate (CR or PR ≥ 24 weeks or SD ≥ 18 months)</measure>
    <time_frame>30 December 2019</time_frame>
    <description>The proportion of subjects whose best overall response is either CR or PR lasting at least 24 weeks, or stable disease (SD) lasting at least 18 months, according to modified RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Durable Response</measure>
    <time_frame>30 December 2019</time_frame>
    <description>Time from documentation of durable response to disease progression or death due to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 12 months</measure>
    <time_frame>30 December 2019</time_frame>
    <description>Time from randomization date to death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <arm_group>
    <arm_group_label>Toca 511/Toca FC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resection followed by administration of 4 mL Toca 511 (vocimagene amiretrorepvec). Toca 511 is administered by injection into the wall of the subject's tumor resection cavity on Day 1 (approximately 40 injections of 0.1 mL)
Toca FC is an extended-release formulation of flucytosine. Toca FC will be administered at 220 mg/kg/day orally for 7-day courses beginning at least 6 weeks after resection and repeated approximately every 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lomustine, Temozolomide, or Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigator selects one of the following:
Bevacizumab: Beginning 6 weeks after tumor resection, bevacizumab will be administered by IV infusion at 10 mg/kg and repeated every 2 weeks. Refer to the prescribing information and to institutional guidelines for details on the administration procedure.
Lomustine: Beginning 6 weeks after tumor resection, lomustine will be administered as a single oral dose of 110 mg/m2 and repeated every 6 weeks. Refer to the prescribing information and to institutional guidelines for details regarding the administration procedure.
Temozolomide: Beginning 6 weeks after tumor resection, temozolomide will be administered per 1 of 2 options:
at a dose of 50 mg/m2 PO once daily continuously, or
at an initial dose of 150 mg/m2 IV or PO once daily for 5 consecutive days per 28-day treatment cycle that may be raised to 200 mg/ m2 once daily for 5 consecutive days in the following 28-day treatment cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Toca 511</intervention_name>
    <description>Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.</description>
    <arm_group_label>Toca 511/Toca FC</arm_group_label>
    <other_name>vocimagene amiretrorepvec</other_name>
    <other_name>RRV</other_name>
    <other_name>retroviral replicating vector</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toca FC</intervention_name>
    <description>Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets</description>
    <arm_group_label>Toca 511/Toca FC</arm_group_label>
    <other_name>flucytosine</other_name>
    <other_name>5-FC</other_name>
    <other_name>5-fluorocytosine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lomustine</intervention_name>
    <arm_group_label>Lomustine, Temozolomide, or Bevacizumab</arm_group_label>
    <other_name>CCNU</other_name>
    <other_name>CeeNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <arm_group_label>Lomustine, Temozolomide, or Bevacizumab</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Lomustine, Temozolomide, or Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has given written informed consent

          2. Subject is between 18 years old and 75 years old, inclusive

          3. Subjects must have histologically proven GBM or AA and:

               1. Must have received first-line multimodal therapy with surgery followed by
                  temozolomide (unless MGMT promoter unmethylated) and radiation (subjects with GBM
                  must have received temozolomide and radiation concurrently)

               2. Must be in first or second recurrence (including this recurrence)

               3. Recurrence must be confirmed by diagnostic biopsy with local pathology review or
                  contrast-enhanced MRI. If first recurrence of GBM is documented by MRI, an
                  interval of at least 12 weeks after the end of prior radiation therapy is
                  required unless there is either: i) histopathologic confirmation of recurrent
                  tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field

          4. Subjects must have measurable disease preoperatively, defined as at least 1
             contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per
             RANO criteria

          5. Subjects must be at least 4 weeks post last dose of temozolomide

          6. Prior gamma knife, stereotactic radiosurgery, or other focal high-dose radiotherapy is
             allowed but the subject must have either histopathologic confirmation of recurrent
             tumor, or new enhancement on MRI outside of the radiotherapy treatment field

          7. Based on the pre-operative evaluation by neurosurgeon, the subject is a candidate for
             ≥ 80% resection of enhancing region

          8. IDH mutation status of the primary tumor must be available or tumor samples must be
             available for pre randomization testing

          9. Laboratory values adequate for patient to undergo surgery, including:

               -  Platelet count ≥ 60,000/mm3

               -  Hgb ≥ 10 g/dL

               -  Absolute neutrophil count (ANC) ≥ 1,500/mm3

               -  Absolute lymphocyte count (ALC) ≥ 500/mm3

               -  Adequate liver function, including:

                    -  Total bilirubin ≤ 1.5 x ULN (unless has Gilbert's syndrome)

                    -  ALT ≤ 2.5 x ULN f. Estimated glomerular filtration rate of at least 50
                       mL/min by the Cockcroft Gault formula

         10. Women of childbearing potential (≥12 months of non-therapy-induced amenorrhea or
             surgically sterile) must have had a negative serum pregnancy test within the past 21
             days and must use a birth control method in addition to barrier methods (condoms).

         11. Subject or subject's partner is willing to use condoms for 12 months after receiving
             Toca 511 or until there is no evidence of the virus in his/her blood, whichever is
             longer.

         12. The subject has a KPS ≥ 70

         13. The subject is willing and able to abide by the protocol

        Exclusion Criteria:

          1. History of more than 2 prior recurrences (including this recurrence) of GBM or AA

          2. History of other malignancy, unless the patient has been disease free for at least 5
             years. Adequately treated basal cell carcinoma or squamous cell skin cancer is
             acceptable regardless of time, as well as localized prostate carcinoma or cervical
             carcinoma in situ after curative treatment

          3. Histologically confirmed oligodendroglioma or mixed glioma

          4. Known 1p/19q co deletion

          5. A contrast enhancing brain tumor that is any of the following:

               -  Multi focal (defined as 2 separate areas of contrast enhancement measuring at
                  least 1 cm in 2 planes that are not contiguous on either fluid attenuated
                  inversion recovery (FLAIR) or T2 sequences);

               -  Associated with either diffuse subependymal or leptomeningeal dissemination; or

               -  &gt; 5 cm in any dimension

          6. The subject has or had any active infection requiring systemic antibiotic, antifungal
             or antiviral therapy within the past 4 weeks

          7. The subject has any bleeding diathesis, or must take anticoagulants, or antiplatelet
             agents, including nonsteroidal anti inflammatory drugs (NSAIDs), at the time of the
             scheduled resection that cannot be stopped for surgery

          8. The subject is human immunodeficiency virus (HIV) positive

          9. The subject has a history of allergy or intolerance to flucytosine

         10. The subject has a gastrointestinal disease that would prevent him or her from being
             able to swallow or absorb flucytosine

         11. The subject received cytotoxic chemotherapy within the past 4 weeks (6 weeks for
             nitrosoureas) of the planned surgery date

         12. The subject received any investigational treatment within the past 30 days or prior
             immunotherapy or antibody therapy within the past 45 days.

         13. The subject is pregnant or breast feeding

         14. The subject intends to undergo treatment with the Gliadel® wafer at the time of this
             surgery or has received the Gliadel® wafer &lt; 30 days from W1D1 (surgery)

         15. The subject has received bevacizumab for their disease unless in the context of
             primary therapy for newly diagnosed glioma

         16. For subjects planned to potentially receive bevacizumab, they have no evidence of
             uncontrolled hypertension (defined as a blood pressure of ≥ 150 mm Hg systolic and/or
             ≥ 100 mm Hg diastolic on medication) or active GI perforation

         17. The subject has received systemic dexamethasone continuously at a dose &gt; 8 mg/day for
             8 weeks prior to the date of the screening assessment

         18. Severe pulmonary, cardiac or other systemic disease, specifically:

               -  New York Heart Association &gt; Grade 2 congestive heart failure within 6 months
                  prior to study entry, unless asymptomatic and well controlled with medication

               -  Uncontrolled or significant cardiovascular disease, clinically significant
                  ventricular arrhythmia (such as ventricular tachycardia, ventricular
                  fibrillation, or Torsades des pointes), clinically significant pulmonary disease
                  (such as ≥ Grade 2 dyspnea, according to CTCAE 4.03)

               -  Subjects who have any other disease, either metabolic or psychological, which as
                  per Investigator assessment may affect the subject's compliance or place the
                  subject at higher risk of potential treatment complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Cloughesy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asha Das, MD</last_name>
    <phone>858-336-0468</phone>
    <email>adas@tocagen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Lovely, PhD, RN</last_name>
    <phone>858-412-8473</phone>
    <email>mlovely@tocagen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norissa Honea</last_name>
      <phone>602-406-6267</phone>
      <email>norissa.honea@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Nader Sanai, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad Alsharif</last_name>
      <phone>714-509-2371</phone>
      <email>alsharim@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Blake Johnson</last_name>
      <phone>714-456-3476</phone>
      <email>blakej@uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniela Bota, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Churas</last_name>
      <phone>858-534-7996</phone>
      <email>bchuras@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>David Piccioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Pham</last_name>
      <email>JenniferPham@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Cloughesy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha French</last_name>
      <phone>714-734-6200</phone>
      <phone_ext>40838</phone_ext>
      <email>martha.french@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Lars Anker, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lizette Upton</last_name>
      <phone>415-353-2582</phone>
      <email>lizette.upton@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas Butowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Bertrand</last_name>
      <phone>650-723-4467</phone>
      <email>sophieb@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Seema Nagpal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Kissane</last_name>
      <phone>720-848-7202</phone>
      <email>rebecca.kissane@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Denise Damek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Martens</last_name>
      <phone>303-357-5446</phone>
      <email>nmartens@thecni.org</email>
    </contact>
    <investigator>
      <last_name>Michael Pearlman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists of Southern Connecticut</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Abrahams</last_name>
      <phone>203-333-1151</phone>
      <phone_ext>8</phone_ext>
      <email>aabrahams@anscneuro.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas Blondin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University/Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tenzin Choezom</last_name>
      <phone>203-737-7981</phone>
      <email>t.choezom@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Moliterno Gunel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida McKnight Brain Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah J Andrews</last_name>
      <phone>352-273-7981</phone>
      <email>Sarah.Andrews@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>David Tran, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Camargo</last_name>
      <phone>305-243-9610</phone>
      <email>vxc316@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Antonio Omuro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Maker</last_name>
      <phone>813-745-1194</phone>
      <email>cheryl.maker@Moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Nam Tran, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Lada, RN</last_name>
      <phone>847-570-2025</phone>
      <email>plada@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Ryan Merrell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sasha Moores</last_name>
      <phone>913-945-7690</phone>
      <email>smoores@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Salacz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Szajna</last_name>
      <phone>410-502-4081</phone>
      <email>kszajna1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Whitney Webb</last_name>
      <phone>410-955-7008</phone>
      <email>wwebb10@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Chetan Bettegowda, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawud Ellayan</last_name>
      <phone>734-615-1749</phone>
      <email>dellayan@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Heth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Korzek</last_name>
      <phone>313-916-1736</phone>
      <email>Ekrozek1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Tobias Walbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital / Allina Health</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Schrecengost</last_name>
      <phone>612-863-6562</phone>
      <email>Amy.schrecengost@allina.com</email>
    </contact>
    <investigator>
      <last_name>John Trusheim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicia O'Neill</last_name>
      <phone>612-626-2569</phone>
      <email>foneill@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Clark Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Midwest / Sarah Cannon</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Stawinski</last_name>
      <phone>816-276-9786</phone>
      <email>sharon.stawinski@hcamidwest.com</email>
    </contact>
    <investigator>
      <last_name>Amandeep Kalra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grayson Talcott</last_name>
      <phone>314-273-0656</phone>
      <email>wu-grayson@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Jian Campian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larisa Skrypnik</last_name>
      <phone>402-559-6745</phone>
      <email>lskrypnik@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Nicole A Shonka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JFK Medical Center Neuroscience Institute</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Porbeni, MD</last_name>
      <phone>732-321-7000</phone>
      <phone_ext>68897</phone_ext>
      <email>cporbeni@jfkhealth.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Landolfi, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Cappello</last_name>
      <phone>551-996-5098</phone>
      <email>lori.cappello@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>George J Kaptain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Overlook Medical Center</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Light</last_name>
      <phone>908-522-5768</phone>
      <email>patrice.light@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Yaron Moshel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Purcell</last_name>
      <phone>516-941-1263</phone>
      <email>lpurcell@nshs.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Schulder, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malcolm DeLara</last_name>
      <phone>212-263-4414</phone>
      <email>Malcolm.Delara@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Dimitris Placantonakis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary O'Hehir</last_name>
      <phone>212-746-7373</phone>
      <email>mao2037@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Rohan Ramakrishna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Busby</last_name>
      <phone>212-305-8487</phone>
      <email>nb2718@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Fabio Iwamoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Serventi</last_name>
      <phone>585-276-3971</phone>
      <email>Jennifer_Serventi@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Nimish Mohile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan M Fiore</last_name>
      <phone>631-444-9425</phone>
      <email>susan.fiore@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Raphael Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Research - Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati's Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Backus</last_name>
      <phone>513-636-2047</phone>
      <email>Lori.backus@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Mariko DeWire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaToya Strickland</last_name>
      <phone>216-844-5071</phone>
      <email>LaToya.Strickland@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Andrew E Sloan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Brewer, RN</last_name>
      <phone>216-444-7937</phone>
      <email>brewerc1@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Biscup, RN</last_name>
      <phone>216-444-2841</phone>
      <email>biscupj@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Vogelbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Arguellovargas</last_name>
      <phone>614-293-6563</phone>
      <email>Erika.Arguellovargas@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Brad J Elder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Coxon</last_name>
      <phone>215-503-5646</phone>
      <email>Andrew.Coxon@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Lyndon Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Levy</last_name>
      <phone>215-662-6832</phone>
      <email>Neurosurgery-NCRD@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Brem, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John &quot;Bo&quot; Keller</last_name>
      <phone>843-792-2209</phone>
      <email>kellerj@musc.edu</email>
    </contact>
    <investigator>
      <last_name>David Cachia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staci Vogel, RN</last_name>
      <phone>605-328-1361</phone>
      <email>staci.vogel@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Miroslaw Mazurczak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Lyons</last_name>
      <phone>615-936-8606</phone>
      <email>katie.lyons@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Reid C Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaMetria West</last_name>
      <phone>214-820-6168</phone>
      <email>lametria.west@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Karen Fink, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital Outpatient Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juli Baskin, RN,BSN</last_name>
      <phone>713-441-3800</phone>
      <email>jabaskin@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>David Baskin, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston (UTHealth)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Pouliot</last_name>
      <phone>713-704-2639</phone>
      <email>susan.m.pouliot@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jay-Jiguang Zhu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Starlene Truslow</last_name>
      <phone>434-243-9360</phone>
      <email>ST3DH@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>David Schiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Dwight and Martha Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tricia Brannan</last_name>
      <phone>703-269-4759</phone>
      <email>tricia.brannan@inova.org</email>
    </contact>
    <investigator>
      <last_name>James Leiphart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Neurosurgery Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Mitchell</last_name>
      <phone>757-388-2533</phone>
      <email>kjmitch1@sentara.com</email>
    </contact>
    <investigator>
      <last_name>Wylie H Zhu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia McEwuen</last_name>
      <phone>304-293-1683</phone>
      <email>smcewuen@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Cifarelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Anger</last_name>
      <phone>608-262-8649</phone>
      <email>anger@humonc.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>John Kuo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Hall</last_name>
      <phone>780-248-5803</phone>
      <email>Stacey.Hall2@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Vivek Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia / Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swetha Prakash</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>62560</phone_ext>
      <email>swetha.rakash@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Brian Toyota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Unit</last_name>
      <phone>204-787-4156</phone>
      <email>ctu_web@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Marshall Pitz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shamim Mortuza</last_name>
      <phone>519-685-8618</phone>
      <email>Shamim.Mortuza@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>David Macdonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn Chambers</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>70955</phone_ext>
      <email>kchambers@toh.on.ca</email>
    </contact>
    <investigator>
      <last_name>Garth Nicholas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Hospital / Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyla Okorofsky</last_name>
      <phone>416-480-5000</phone>
      <phone_ext>7474</phone_ext>
      <email>hyla.okorofsky@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>James Perry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takyee Tung</last_name>
      <phone>416-603-5800</phone>
      <phone_ext>5578</phone_ext>
      <email>Takyee.tung@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Gelareh Zadeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Nezvitsky</last_name>
      <phone>514-398-2801</phone>
      <email>lisa.nezvitsky@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Kevin Petrecca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sherbrooke Hospital University Centre (CHUS)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anick Champoux, RN</last_name>
      <phone>1-819-346-1110</phone>
      <phone_ext>12811</phone_ext>
      <email>achampoux.chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>David Mathieu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min-Jung Park</last_name>
      <phone>82-2-2072 0347</phone>
      <email>juli21@naver.com</email>
    </contact>
    <investigator>
      <last_name>Chul-Kee Park, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Sim Park</last_name>
      <phone>82-2-10-3231-4731</phone>
      <email>como_7@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jong Hee Chang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi Jin Choi</last_name>
      <phone>+82-2-3410-3721</phone>
      <email>mj78.choi@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Do-Hyun Nam, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su Youn Lee</last_name>
      <phone>82-2-2258-2796</phone>
      <email>eupnea20@naver.com</email>
    </contact>
    <investigator>
      <last_name>Sin-Soo Jeun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Lomustine</mesh_term>
    <mesh_term>Flucytosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

